Effect of abrocitinib vs dupilumab and placebo on patient-reported outcomes (PROs) in moderate-to-severe atopic dermatitis (AD) in JADE COMPARE

被引：0

作者：

Yosipovitch, Gil ^{[1
]}

Thyssen, Jacob P. ^{[2
]}

Paul, Carle ^{[3
,4
]}

Kwatra, Shawn G. ^{[5
]}

Chu, Chia-Yu ^{[6
,7
]}

Rojo, Ricardo ^{[8
]}

Valdez, Hernan ^{[8
]}

Feeney, Claire ^{[9
]}

Zhang, Fan ^{[8
]}

Myers, Daniela E. ^{[8
]}

DiBonaventura, Marco ^{[8
]}

机构：

[1] Univ Miami, Miller Sch Med, Miami Itch Ctr, Coral Gables, FL 33124 USA

[2] Univ Copenhagen, Herlev Gentofte Hosp, Copenhagen, Denmark

[3] Toulouse Univ, Toulouse, France

[4] CHU, Toulouse, France

[5] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA

[6] Natl Taiwan Univ Hosp, Taipei, Taiwan

[7] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[8] Pfizer Inc, New York, NY USA

[9] Pfizer Ltd, New York, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

27237

引用

页码：AB133 / AB133

页数：1